Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity

ABSTRACT: The effect of T372E-EZH2 and Wt-EZH2 overexpression on gene expression in TOV112D cells. We found in this study that Protein Kinase A phosphorylates T372-EZH2 and wanted to determine the gene expression changes brought upon this phosphorylation. We made a point mutation (T372E) that mimicked phospho T372-EZH2. The objective was to observe transcriptional changes in TOV112D cells in response to ectopic expression of Wt-EZH2 and T372E-EZH2 point mutation in TOV112D cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE108418 | GEO | 2018/06/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Nucleosome positioning in H3S57 mutants in yeast

Project description:In order to test the effect of H3S57 phosphorylation on nucleosome positioning in yeast, nucleosome were mapped in a WT strain, a strain with H3S57A mutation (phospho absent) and a strain H3S57E mutation (phospho mimicking).

2020-12-20 | E-MTAB-6901 | biostudies-arrayexpress

EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition

Project description:The purpose of this research is to study the mechanism of the synergistic effect combining EZH2 inhibition and PI3K inhibition. In this study, we observed that the PIK3CA-mutant or amplified lung cancer cells were more sensitive to EZH2 inhibition. PIK3CA E545K, the most common mutation in lung cancer, harbored a modest transformation capacity along with p53 loss in lung epithelial cells, and developed adenocarcinoma autochthonously. EZH2 inhibitor synergized with PI3K inhibitor in human cancer cells in vitro and worked together efficiently in vivo. Mechanistically, EZH2 inhibition cooperated with PI3K inhibition to produce a more potent suppression of phospho-AKT downstream of PI3K.

2021-10-12 | GSE183818 | GEO

Mst1-mediated phosphorylation of FoxO1 and C/EBP-β Stimulates Cell-protective Mechanisms in Cardiomyocytes

Project description:The molecular mechanisms by which FoxO transcription factors mediate diametrically opposite cellular responses, namely death and survival, remain unknown. Mst1 phosphorylates FoxO1 Ser209/Ser215/Ser218/Thr228/Ser232/Ser243, thereby inducing nuclear translocation of FoxO1 in cardiomyocytes. Mst1 inhibits the FoxO1-mediated transcription of proapoptotic genes but promotes that of prosurvival genes. Mst1 increases FoxO1-C/EBP-β interaction and phosphorylates C/EBP-β at Thr299, thereby promoting transcription of prosurvival genes. Myocardial ischemia/reperfusion (I/R) injury was larger in cardiac-specific FoxO1 knockout (c-FoxO1–/–) mice than in control mice. However, the concurrent presence of C/EBP-β T299E phospho-mimetic mutation reduced infarct size in c-FoxO–/– mice. The C/EBP-β phospho-mimetic mutant exhibited a higher binding to the promoter of prosurvival genes compared to wild-type C/EBP-β. In conclusion, phosphorylation of FoxO1 by Mst1 inhibits the binding of FoxO1 to pro-apoptotic gene promoters but enhances its binding to C/EBP-β, phosphorylation of C/EBP-β, and transcription of prosurvival genes, which stimulate protective mechanisms in the heart.

2022-09-12 | GSE213010 | GEO

Phosphorylation and stabilization of EZH2 by VprBP trigger aberrant gene silencing in colon cancer

Project description:Our recent work has shown that VprBP is overexpressed in colon cancer and phosphorylates histone H2AT120 to drive epigenetic gene inactivation and oncogenic transformation. We have extended these observations by investigating whether VprBP also phosphorylates non-histone proteins as an additional mechanism linking its kinase activity to colon cancer development. We now demonstrate that VprBP directly phosphorylates EZH2 at T367 to augment its nuclear stabilization and enzymatic activity in colon cancer cells. Consistent with this mechanistic role, VprBP-mediated EZH2 phosphorylation leads to elevated levels of H3K27me3 and altered expression of growth regulatory genes in cancer cells. Furthermore, our preclinical studies using organoid and xenograft models revealed that EZH2 requires phosphorylation for its oncogenic function, which may have therapeutic implications for gene reactivation in colon cancer cells. Together, our data define a new mechanism underlying VprBP-driven colonic tumorigenesis by linking VprBP-mediated EZH2 phosphorylation to EZH2 stability that is crucial for establishing H3K27me3 and gene silencing program.

2023-03-28 | GSE192489 | GEO

RNA sequencing data from MCF7 luminal breast cancer cells expressing STAT5a phospho-point mutants

Project description:Purpose: The goal of this study was to generate mRNA profiles for MCF7 breast cancer cells expressing phospho-deficient STAT5a point mutants with treatment of prolactin (PRL) to determine differential global genomic effects in breast cancer. This data was compared to in vitro studies using the same cells to determine phenotypic outcomes of the STAT5a point mutations. Methods: mRNA profiles of prolactin (PRL) treated or untreated MCF7 cells expressing wild type (WT)-STAT5a, or phospho-deficient point mutants Y694F-, S726A-, or S780A-STAT5a were generated in triplicate by sequencing on the S4 flow cell platform of the Illumina NovaSEQ 6000 System (Illumina, Inc), generating ≥50 million 150 bp paired-end (PE) reads per sample. All libraries were prepared and sequenced in a single batch/flow cell lane. Results: RNA-sequencing and subsequent Ingenuity Pathway Analysis predicted that loss of each phospho-site differentially affected both prolactin-induced gene expression as well as functional pathways of breast cancer (e.g. cell survival, proliferation, and colony formation). Gene set analysis for transcription factor activity (using ENCODE project ChIP-sequencing and the web platform Enrichr), illustrated multiple transcription factors at work in MCF7 cells expressing each phospho-deficient STAT5a point mutant, indicating that these point mutants have roles regulating STAT5a activity at various enhancer/promoters in a enhancer/promoter specific context. Conclusion:

2021-07-07 | GSE165678 | GEO

RNA-seq of murine Th1 and Th2 cells differentiated for 24hr with or without the presence of actin and EZH2 inhibitors

Project description:CD4 T helper cells can differentiate to several types of cells like Th1, Th2, Th17 and Treg. This process is directed by cytokines and activation of T cells by specific antigens. This process has its own plasticity and it is directed by epigenetic changes allowing cells to develop and differentiate. In this experiment, we wanted to explore if EZH2 has a transcriptional regulation in the first day of differentiation. To study this we performed RNA-seq with or without UNC1999, an EZH2 inhibitor. Moreover, we wanted to learn the interaction between EZH2 and nuclear Actin, so Cytochalasin B was added to look for similar transcriptional pattern.

2021-08-28 | E-MTAB-9523 | biostudies-arrayexpress

Expression profiling of AMPK-regulated genes in mouse embryonic fibroblast cells

Project description:We used RNA-Seq assay to characterize AMPK-regulated gene expression patterns and then compared with EZH2-dependent transcriptional profile in MEF. We wanted to determine whether and how AMPK and EZH2 co-regulate a subset of genes.

2017-12-15 | GSE97735 | GEO

Development of gene expression signatures for MCF10A cell lines carrying HER2 and WT or H1047R PIK3CA oncogenes.

Project description:We wanted to know how introduction of H1047R oncogenic mutation of PIK3CA (p110a subunit of PI3K) in HER2-overexpressing MCF10A human non-transformed mammary epitheial cell lines introduces change in gene expression levels. Our control was HER2-overexpressing MCF10A cell line with wild-type (WT) PIK3CA. Mutated oncogene-induced gene expression signature was measured and compared with that induced by the WT oncogene from cell lines harvested at 70-80% confluency.

2021-03-16 | GSE117389 | GEO

Ezh2Y641F mutations co-operate with Stat3 to enhance MHC Class I antigen processing and alter the tumor immune response in melanoma

Project description:Enhancer of Zeste Homolog 2 (EZH2) is the catalytic component of the Polycomb Repressive Complex 2, a chromatin modifying complex, which mediates methylation of lysine 27 on histone 3 (H3K27me3), a repressive chromatin mark. Genetic alterations in EZH2 in melanoma include amplifications and activating point mutations at tyrosine 641 (Y641) whose underlying oncogenic mechanisms remain largely unknown. Here, we found that expression of Ezh2Y641F causes upregulation of a subset of interferon-regulated genes in melanoma cells. Upregulation of these genes was not a direct effect of changes in H3K27me3, but via a non-canonical interaction between Ezh2 and Signal Transducer and Activator of Transcription 3 (Stat3). Ezh2 and Stat3 together function as transcriptional activators to mediate gene activation of numerous genes, including MHC-Ib antigen processing genes. Furthermore, expression of Stat3 is required to maintain an anti-tumor immune response in Ezh2Y641F melanomas and to prevent melanoma progression and recurrence.

2022-09-30 | GSE183819 | GEO

Chip-chip from undifferentiated and neuron-differentiated hMSCs cells with EZH2

Project description:EZH2 plays an important role in stem cell renewal and maintenance by inducing gene silencing via its histone methyltransferase activity. Previously, we showed EZH2 downregulation markedly enhances neuron differentiation of human mesenchymal stem cells (hMSCs). To understand how EZH2 regulates neuron differentiation of hMSCs, we wanted to identify the target genes of EZH2. For this reasons we performed ChIP-on-chip experiments using specific EZH2 antibodies followed by a human promoter array for the whole human genome.

2012-12-05 | GSE42686 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data